« Return to News | Awards & Advancement

Unigene appoints Mayes and Pepper to biotechnologies SBU

Friday, February 10, 2012 11:48 AM

Unigene Laboratories announced the expansion of its biotechnologies strategic business unit (SBU) with the promotion of Gregory T. Mayes to chief business officer and appointment of Jane Pepper to senior director, business development.

Gregory T. Mayes, Esq. previously held the Unigene position of vice president of corporate development and general counsel, the latter which he will retain with his appointment to chief business officer. Mayes has been an integral part of the turnaround management team that spearheaded Unigene's successful rescue in 2011.  He also has been instrumental securing an impressive eight new therapeutic peptide oral drug delivery feasibility studies during the second half of last year.

Jane Pepper, M.B.A, Ph.D., previously was in the development organization of Novartis Pharmaceuticals. She will be responsible for further leveraging Unigene's Peptelligence platform for the oral drug delivery of therapeutic peptides across a broad spectrum of disease areas by continuing to build a robust portfolio of strategically partnered opportunities.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.